- Home
- COKE vs EXEL Comparison
COKE vs EXEL Comparison
Compare COKE & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COKE | EXEL |
|---|---|---|
| Founded | 1902 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 12.7B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | COKE | EXEL |
|---|---|---|
| Price | $189.36 | $58.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $46.50 |
| AVG Volume (30 Days) | 431.2K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 156.81 | 57.95 |
| EPS | 1.21 | ★ 1.60 |
| Revenue | ★ $7,228,055,000.00 | $452,477,000.00 |
| Revenue This Year | N/A | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | $156.74 | ★ $36.22 |
| Revenue Growth | ★ 4.76 | N/A |
| 52 Week Low | $114.50 | $33.76 |
| 52 Week High | $218.73 | $59.72 |
Technical Indicators
Market Signals| Indicator | COKE | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 55.80 |
| Support Level | $184.25 | $54.38 |
| Resistance Level | $198.41 | $59.44 |
| Average True Range (ATR) | 5.26 | 1.59 |
| MACD | -0.94 | -0.06 |
| Stochastic Oscillator | 30.70 | 73.38 |
Price Performance
Historical ComparisonAbout COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets, and manufactures nonalcoholic beverages. It offers a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages, and the Company's principal sparkling beverage is Coca-Cola. Still beverages include energy products and non-carbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices, and sports drinks. The Company has two operating segments: Nonalcoholic Beverages and All Other. Key revenue is generated from Nonalcoholic Beverages.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.